Biolife Solutions (BLFS) Common Equity (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of Common Equity data on file, last reported at $372.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at $372.2 million, up 5.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $372.2 million (up 5.56% YoY), and the FY2025 annual result was $371.9 million, up 6.59% from the prior year.
• Common Equity was little changed at $372.2 million in Q1 2026 per BLFS's latest filing, from $371.9 million in the prior quarter.
• Over five years, Common Equity peaked at $476.1 million in Q1 2022 and troughed at $321.4 million in Q2 2024.
• A 5-year average of $362.5 million and a median of $352.6 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity surged 128.03% in 2022, then fell 24.78% in 2023.
• A 5-year view of Common Equity shows it stood at $364.2 million in 2022, then declined by 7.28% to $337.7 million in 2023, then advanced by 3.33% to $348.9 million in 2024, then climbed by 6.59% to $371.9 million in 2025, then gained by 0.09% to $372.2 million in 2026.
• Business Quant data shows BLFS's Common Equity at $372.2 million in Q1 2026, $371.9 million in Q4 2025, and $353.7 million in Q3 2025.